Protective effect of teprenone against acute gastric mucosal lesions induced by compound 48/80, a mast cell degranulator, in rats

Journal of Pharmacological Sciences

Volumn 93, Issue 3, 2003, Pages 337-346

  Ohta, Yoshiji ^a   Kobayashi, Takashi ^b   Inui, Kazuo ^b   Yoshino, Junji ^b   Nakazawa, Saburo ^b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Compound 48 80; Gastric mucosal lesion (rat); Gastric mucus; Neutrophil infiltration; Teprenone

Indexed keywords

ANTIULCER AGENT; COMPOUND 48-80; EDETIC ACID; HEXOSAMINE; HISTAMINE; MARKER; MYELOPEROXIDASE; N(G) METHYL DEXTRO ARGININE; N(G) METHYLARGININE; SEROTONIN; TEPRENONE; THIOBARBITURIC ACID; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; HISTAMINE BLOOD LEVEL; LIPID PEROXIDATION; MALE; MAST CELL DEGRANULATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; RAT; SEROTONIN BLOOD LEVEL; STIMULATION; STOMACH BLOOD FLOW; STOMACH MUCOSA LESION;

ACUTE DISEASE; ANIMALS; CELL DEGRANULATION; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTRIC MUCOSA; MALE; MAST CELLS; P-METHOXY-N-METHYLPHENETHYLAMINE; RATS; RATS, WISTAR; STOMACH ULCER;

EID: 0348136062     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.93.337     Document Type: Article

References (50)

1. Arakawa T, Yamada H, Nakamura A, et al. Gastric cytoporotection by tetraprenylacetone in human subjects. Digestion. 1994;39:111-117.
2. Shirakabe H, Takemoto T, Kobayashi K, et al. Clinical evaluation of teprenone, a mucosal protective agent, in the treatment of patients with gastric ulcers: A nationwide, multicenter clinical study. Clin Ther. 1995;17:924-935. (text in Japanese with English abstract)
3. Ngasawa Y, Tatsuta M, Ishi H, Ishiguro S. Prevention of gastric ulcer recurrence with tetraprenylacetone. Scand J Gasteroneterol. 1998;33:44-48.
4. Terano A, Hiraishi H, Ota S, Sugimoto T. Geranylgeranylacetone, a novel anti-ulcer drug, stimulates mucus synthesis and secretion in rat gastric cultured cells. Digestion. 1986;33:206-210.
5. Hassan S, Kinoshita Y, Okada A, Maekawa T, Fukui H, Chiba T. Geranylgeranylacetone, an anti-ulcer drug, stimulates hexosamine production in a rat mucosal cell line through binding to a specific cytosolic protein. J Gastroenterol Hepatol. 1998;13:809-815.
6. Rokutan K, Teshima S, Kawai T, et al. Geranylgeranylacetone stimulates mucin synthesis in cultured guinea pigs gastric pit cells by inducing a neuronal nitric oxide synthease. J Gastroenterol. 2000;35:673-681.
7. Tatsuta M, Yamamoto R, Iishi H, Nakaizumi A. Scanning electron microscopic observation on gastric mucus secretion in rats, and the effects of tetraprenylacetone. Digestion. 1995;56:175-180.
8. Nishida K, Ohta Y. Terenone, an anti-ulcer agent, increases gastric mucosal mucus level via nitric oxide in rats. Jpn J Pharmacol. 1998;78:519-522.
9. Nakazawa S, Tsuboi Y, Tsukamoto Y, Yoshino J, Okada M. Serum and stomach tissue levels of geranylgeranylacetone in patients. Int J Clin Pharmacol Ther Toxicol. 1983;21:267-270.
10. Murakami M, Oketani K, Fujisaki H, Wakabayashi T, Ohgo T. Antiulcer effect of geranylgeranylacetone, a new acylic polyisoprenoid on experimentally induced gastric and duodenal ulcers in rats. Arzneimittelforschung. 1981;31:799-804.
11. Murakami M, Oketani K, Fujisaki H, Wakabayashi T, Ohgo T. Effects of the antiulcer drug geranylgeranylacetone on asprin-induced gastric ulcers in rats. Jpn J Pharmacol. 1982;32:299-306.
12. Itoh Y, Suzuki K, Matsubara M, Takeyama N, Kitazawa Y, Tanaka T. Changes in gastric mucosal content of adenosine, xanthine and hypoxanthine induced by restrained water immersion stress: Antiulcer effects of tetraprenylacetone. Digestion. 1991;48:25-33.
13. Nishida K, Ohta Y, Ishiguro I. Protective and preventive effects of teprenone on gastric mucosal lesions in rats. Eur J Pharmacol. 1998;354:51-58.
14. Saita H, Murakami M. Effect of teprenone on gastric mucosal injury induced by Helicobacter pylori in rats. Arzneimittelforschung. 2000;50:1110-1114.
15. Kobayashi T, Ohta Y, Yoshino J, Nakazawa S. Terenone promotes the healing of acetic acid-induced chronic ulcers in rats by inhibiting neutrophil infiltration and lipid peroxidation in ulcerated gastric tissues. Pharmacol Res. 2001;43:23-30.
16. Hiraishi H, Terano A, Ota S, et al. Role for mucous glycopotein in protecting cultured rat gastric mucosal cells against toxic oxygen metabolites. J Lab Clin Med. 1993;12:570-578.
17. Grisham MB, Von Ritter C, Smith BF, LaMont JT, Granger DN. Interaction between oxygen radicals and gastric mucin. Am J Physiol. 1987;253:G93-G96.
18. Yoshikawa T, Naito J, Yoshida M, Kondo M. Mechanism in gastro-intestinal mucosal injury induced by activated neutrophils. Microcirc Ann. 1999;15:31-32.
19. Enerback L, Lundin PM. Ultrastructure of mast cells in normal and compound 48/80-treated rats. Cell Tissue Res. 1974;150:95-105.
20. Irman-Florjanc T, Erjavec F. Compound 48/80 and substance P induced release of histamine and serotonin from peritoneal mast cells. Agents Actions. 1983;13:138-141.
21. Ohta Y, Kobayashi T, Nishida K, Ishiguro I. Relationship between changes of active oxygen metabolism and blood flow and formation, progression, and recovery of lesions in gastric mucosa of rats with a single treatment of compound 48/80, a mast cell degranulator. Dig Dis Sci. 1997;42:1221-1232.
22. Ohta Y, Kobayashi T, Ishiguro I. Participation of xanthine-xanthine oxidase system and neutrophils in development of acute gastric mucosal lesions in rats with a single treatment of compound 48/80, a mast cell degranulator. Dig Dis Sci. 1999;44:1865-1874.
23. Ohta Y, Kobayashi T, Ishiguro I. Role of endogenous serotonin and histamine in the pathogenesis of gastric mucosal lesions in unanesthetised rats with a single treatment of compound 48/80, a mast cell degranulator. Pharmacol Res. 1999;39:261-267.
24. Kobayashi T, Ohta Y, Yoshino J. Preventive effect of ebselen on acute gastric mucosal lesion development in rats treated with compound 48/80. Eur J Pharmacol. 2001;414:271-279.
25. Ohta Y, Kobayashi T, Inui K, Yoshino J, Nakazawa S. Protective effect of ebselen, a seleno-organic compound, against the progression of acute gastric mucosal lesions induced by compound 48/80, a mast cell degranulator, in rats. Jpn J Pharmacol. 2002;90:295-303.
26. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344-1350.
27. Suzuki K, Ota H, Sasagawa S, Sakatani T, Fujikura T. Assay method of myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem. 1983;132:345-353.
28. Hashimoto S. New spectrophotometric assay method of xanthine oxidase in crude tissue homogenate. Anal Biochem. 1974;62:426-433.
29. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358.
30. Neuhaus OW, Letzring M. Determination of hexosamine in conjunction with electrophoresis. Anal Chem. 1957;29:1230-1233.
31. Kitagawa H, Takada F, Kohei H. A simple method for estimation of gastric mucus and effects of antiulcerogenic agents on the decrease in mucus during water-immersion stress in rats. Arzneimittelforschung. 1986;36:1240-1244.
32. ω-methyltryptamine, as an internal standard in biological materials by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1988;430:381-387.
33. Lorenz W, Reimann H-J, Barth H, et al. A sensitive and specific method for the determination of histamine in human whole blood and plasma. Hoppe Seylers Z Physiol Chem. 1972;353:911-920.
34. Shore PA, Burkhalter A, Cohn VH Jr. A method for the fluorometric assay of histamine in tissue. J Pharmacol Exp Ther. 1959;127:182-186.
35. Hachiya A, Bassho M, Iwasaki T, Iida K, Otsuka S. Protective effect on blood flow and incidence of histologic lesions in rat gastric mucosa after hemorrhage and retransfusion. Scand J Gastroenterol. 1996;31:326-333.
36. Morimoto Y, Shimohara K, Oshima S, Sukamoto T. Effects of the new anti-ulcer agent KB0-5492 on experimental gastric mucosal lesions and gastric mucosal defensive factors, as compared to those of teprenone and cimetidine. Jpn J Pharmacol. 1991;57:495-505.
37. Fridovich I. Quantitative aspects of the production of superoxide anion radical by milk xanthine oxidase. J Biol Chem. 1970;41:4053-4057.
38. Porras AG, Olson J, Plamer G. The reaction of xanthine oxidase with oxygen. Kinetics of peroxide and superoxide. J Biol Chem. 1981;256:9096-9103.
39. 3+-ADP-dependent lipid peroxidation in negatively charged phospholipids vesicles. Arch Biochem Biophys. 1995;316:83-91.
40. Zimmerman JJ, Ciesielski W, Lewandoski J. Neutrophil-mediated phospholipid peroxidation assessed by gas chromatography-mass spectroscopy. Am J Physiol. 1997;273:G653-G661.
41. Stelmaszynska T, Kukovetz E, Egger G, Schaur RJ. Possible involvement of myeloperoxidase in lipid peroxidation. Int J Biochem. 1992;24:121-128.
42. Kanuitz JD. Barrier function of gastric mucus. Keio Med J. 1999;48:63-68.
43. Seno K, Joh T, Yokoyama Y, Itoh M. Role of mucus in gastric mucosal injury induced by local ischemia/reperfusion. J Lab Clin Med. 1995;126:287-293.
44. Nishida K, Ohta Y, Ishiguro I. Preventive effect of teprenone on stress-induced gastric mucosal lesions and its relation to gastric mucosal constitutive nitric oxide synthase activity. Pharmacol Res. 1999;39:325-332.
45. Kim H, Kim KH. Role of nitric oxide and mucus in ischemia/reperfusion-induced gastric mucosal injury in rats. Pharmacology. 2001;62:200-207.
46. Mikami Y, Mizuno M, Naga T, et al. Geranylgeranylacetone and cetraxate hydrochloride increase UDP-galactosyltransferase activity in rat gastric mucosa. Acta Med Okayama. 1997;51:245-249.
47. Terano A, Shiga J, Hiraishi H, Ota S, Sugimoto T. Protective action of tetraprenylacetone against ethanol-induced damage in rat gastric mucosa. Digestion. 1986;35:182-188.
48. Bilski J, Murty VLN, Nadziejko C, et al. Protection against alcohol-induced gastric mucosal injury by geranylgeranylacetone: Effect of indomethacin. Digestion. 1988;41:22-33.
49. Ohta Y, Koabayashi K, Yoshino J, Nakazawa S. Effects of arachidonic acid metabolism-related enzyme inhibitors in compound 48/80-induced acute gastric mucosal lesions. Ulcer Res. 2003;30:65-69. (text in Japanese with English abstract)
50. Hsu H-C, Flancbaum LJ, Kasziba E, Merrill GF, Fisher H. Roles of in vitro- and in vivo-administered histamine and serotonin in compound 48/80-induced gastric acid secretion in isolated, perfused rat stomach. Dig Dis Sci. 1991;1708-1714.